Adjuvant gastric cancer : TNM Stage II (exclude T1)、IIIA、IIIB; Unresectable advanced gastric cancer. (Taiwan)

Combination endocrine therapy as postoperative adjuvant treatment for early breast cancer.<2024/9/20>

TS-1is composed of tegafur, gimestat and otastat potassium at a molar ratio of 1:0.4:1, and the antitumor activity of TS-1 after oral administration is based on 5-FU. Tegafur (FT) is considered to be a prodrug of 5-fluorouracil, exerting activity after conversion to 5-fluorouracil in the liver. Gimeracil (CDHP)increased the concentration of 5-FU, which is converted from tegafur, by selectively and reversibly inhibiting DPD. Oteracil potassium(Oxo) selectively inhibits the production of 5-fluoronucleotides from 5-FU by distributing in the gastrointestinal tissue as a result of oral administration and selectively and reversibly inhibiting orotate phosphoribosyltransferase. Gastrointestinal toxicity appears to be relieved as a result, without interfering with the antitumor activity of 5-FU.

The amount excreted in the urine within 72 hours after administration accounted for 52.8% of the gimeracil, 7.8% of the tegafur, 2.2% of the oteracil potassium, 11.4% of the metabolite cyanuric acid and 7.4% of the fluorouracil (5-FU). (oral dose of 32-40 mg/m2 after a meal); It has been reported that CYP2A6 is the major cytochrome P450 isoenzymes in human liver microsomes involved in the metabolic transformation of FT to 5-FU (in vitro).

severe bone marrow depression; concomitant use with other fluoropyrimidines; dihydropyrimidine dehydrogenase deficiency; ESRD requiring dialysis; hypersensitivity to tegafur, gimeracil, oteracil, or any component of the product; pregnancy or breastfeeding; severe and unexpected reactions to fluoropyrimidine therapy; treatment within 4 weeks with dihydropyrimidine dehydrogenase inhibitors, including sorivudine or chemically related analogs (eg, brivudine).

X

Avoided

Most common: thrombocytopenia, anemia, nausea, vomiting, anorexia, increased AST/ALT, stomatitis, pigmentation, rash; Severe: Neutropenia, diarrhea.

通常為依據體表面積之成人初始劑量(單次劑量)。
TS-1於早、晚餐後一天共兩次給藥，連續給予28天，之後停藥14天，即為一個療程。

The initial dose for adults is usually based on body surface area (single dose).
TS-1 is administered twice daily after breakfast and dinner for a total of 28 days, followed by a 14-day break, constituting one treatment cycle.

大腸直腸癌

TS-1與Irinotecan合併使用。
TS-1的劑量根據病人體表面積，每天兩次，連續吃兩週，接著休息兩週，重複以上方式治療。

TS-1 is used in combination with Irinotecan for colorectal cancer.The dose of TS-1 is based on the patient's body surface area, taken twice daily for two weeks, followed by a two-week break, and this cycle is repeated.

晚期非小細胞肺癌

TS-1的劑量根據病人體表面積，於早、晚餐後一天共兩次給藥，連續給予28天，接著休息14天。

The dose of TS-1 is based on the patient's body surface area, administered twice daily after breakfast and dinner for 28 days, followed by a 14-day break.

膽道癌

TS-1與Gemcitabine合併使用，治療晚期或復發之膽道癌。
TS-1的劑量根據病人體表面積於早、晚餐後一天共兩次給藥，連續給予14天，接著休息7天。

TS-1 is used in combination with Gemcitabine to treat advanced or recurrent biliary tract cancer.
The dose of TS-1 is based on the patient's body surface area, administered twice daily after breakfast and dinner for 14 days, followed by a 7-day break.

具有高復發風險的HR陽性和HER2陰性乳癌之術後輔助化療

TS-1初始劑量依據體表面積決定，於早、晚餐後合併內分泌療法一天共兩次給藥，連續給予14天，之後停藥7天，即為一個療程。

The initial dose of TS-1 is determined based on body surface area, administered twice daily after breakfast and dinner in combination with endocrine therapy for 14 days, followed by a 7-day break, constituting one treatment cycle.<2024/9/20>

Dosage adjustment:
For patients with moderate renal impairment (CrCl, 30 to 50 mL/min): 20 mg/m2 orally twice daily (expressed as tegafur content) on days 1 through 21 of a 28-day cycle.Use in patients with severe renal impairme